KCNJ11 and type 2 diabetes mellitus: Despite the absence of monoclonal antibodies against known type-2 diabetes small molecule targets ABCC8, ABCC9, DPP4, and KCNJ11, these genes demonstrated AB tractability estimates greater than 60%, along with interleukin receptors IL4R and IL17RA (Fig. 2D).